These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35995727)

  • 21. Corrigendum to "Sinomenine inhibits fibroblast-like synoviocyte proliferation by regulating α7nAChR expression via ERK/Egr-1 pathway" [Int. Immunopharmacol. 56 (2018) 65-70].
    Yi L; Lyu YJ; Peng C; Zhu RL; Bai SS; Liu L; Wang PX; Zhou H; Dong Y
    Int Immunopharmacol; 2018 Sep; 62():339. PubMed ID: 30007832
    [No Abstract]   [Full Text] [Related]  

  • 22. Corrigendum to "Sodium houttuyfonate enhances the intestinal barrier and attenuates inflammation induced by Salmonella typhimurium through the NF-κB pathway in mice" [Int. Immunopharmacol. 89 (2020) 107058].
    Zhang L; Lv H; Li Y; Dong N; Bi C; Shan A; Wu Z; Shi B
    Int Immunopharmacol; 2021 Mar; 92():107351. PubMed ID: 33444920
    [No Abstract]   [Full Text] [Related]  

  • 23. Corrigendum to "In vivo anti-apoptosis activity of novel berberine-loaded chitosan nanoparticles effectively ameliorates osteoarthritis" [Int. Immunopharmacol. 28(1) (2015) 34-43].
    Zhou Y; Liu SQ; Peng H; Yu L; He B; Zhao Q
    Int Immunopharmacol; 2022 Jul; 108():108844. PubMed ID: 35562271
    [No Abstract]   [Full Text] [Related]  

  • 24. Corrigendum to "In vivo anti-apoptosis activity of novel berberine-loaded chitosan nanoparticles effectively ameliorates osteoarthritis" [Int. Immunopharmacol. 28(1) (2015) 34-43].
    Zhou Y; Liu SQ; Peng H; Yu L; He B; Zhao Q
    Int Immunopharmacol; 2020 Sep; 86():106796. PubMed ID: 32674050
    [No Abstract]   [Full Text] [Related]  

  • 25. Corrigendum to "Mechanistic efficacy assessment of selected novel methanimine derivatives against vincristine induced Neuropathy: In-vivo, Ex-vivo and In-silico correlates" [Int. Immunopharmacol. 112 (2022) 109246].
    Khan J; Ali G; Khurshid A; Saeed A; Ahmad S; Ullah N; Khan A; Sewell RDE; Zakria M
    Int Immunopharmacol; 2023 Apr; 117():109958. PubMed ID: 36907789
    [No Abstract]   [Full Text] [Related]  

  • 26. Corrigendum to "Taxifolin ameliorates Benzo[a]pyrene-induced lung injury possibly via stimulating the Nrf2 signalling pathway" [Int. Immunopharmacol. 96 (2021) 107566].
    Islam J; Shree A; Vafa A; Afzal SM; Sultana S
    Int Immunopharmacol; 2023 Jun; 119():110096. PubMed ID: 37095029
    [No Abstract]   [Full Text] [Related]  

  • 27. Corrigendum to "Ghrelin attenuates secondary brain injury following intracerebral hemorrhage by inhibiting NLRP3 inflammasome activation and promoting Nrf2/ARE signaling pathway in mice" [Int. Immunopharmacol. 79 (2020) 106180].
    Cheng Y; Chen B; Xie W; Chen Z; Yang G; Cai Y; Shang H; Zhao W
    Int Immunopharmacol; 2020 Jul; 84():106461. PubMed ID: 32278662
    [No Abstract]   [Full Text] [Related]  

  • 28. Corrigendum to "Tanshinone IIA ameliorates the bleomycin-induced endothelial-to-mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis" [Int. Immunopharmacol. 77 (2019) 105968].
    Jiang Y; Hu F; Li Q; Shen C; Yang J; Li M
    Int Immunopharmacol; 2020 Jul; 84():106318. PubMed ID: 32115350
    [No Abstract]   [Full Text] [Related]  

  • 29. Corrigendum to "Isosteroid alkaloids with different chemical structures from Fritillariae cirrhosae bulbus alleviate LPS-induced inflammatory response in RAW 264.7 cells by MAPK signaling pathway" [Int. Immunopharmacol. 78 (2020) 106047].
    Liu S; Yang T; Ming TW; Gaun TKW; Zhou T; Wang S; Ye B
    Int Immunopharmacol; 2020 Jul; 84():106482. PubMed ID: 32278661
    [No Abstract]   [Full Text] [Related]  

  • 30. Corrigendum to "Intravenous immunoglobulin alleviates Japanese encephalitis virus-induced peripheral neuropathy by inhibiting the ASM/ceramide pathway" [Int. Immunopharmacol. 133 (2024) 112083].
    Zhang N; Wang G; Yang L; Zhang J; Yuan Y; Ma L; Wang H; Wang Z
    Int Immunopharmacol; 2024 Jun; 134():112270. PubMed ID: 38762402
    [No Abstract]   [Full Text] [Related]  

  • 31. Corrigendum to "Alpha-Mangostin suppresses interleukin-1β-induced apoptosis in rat chondrocytes by inhibiting the NF-κB signaling pathway and delays the progression of osteoarthritis in a rat model" [Int. Immunopharmacol. 52 (2017) 156-162].
    Pan T; Chen R; Wu D; Cai N; Shi X; Li B; Pan J
    Int Immunopharmacol; 2018 Dec; 65():559-560. PubMed ID: 30412853
    [No Abstract]   [Full Text] [Related]  

  • 32. Corrigendum to "The -172 A-to-G variation in ADAM17 gene promoter region affects EGR1/ADAM17 pathway and confers susceptibility to septic mortality with sepsis-3.0 criteria" [Int. Immunopharmacol. 102 (2022) 108385].
    He J; Zhao T; Liu L; Liao S; Yang S; Lu F; Hong Y; Wei N; Cheng H; Zhang W; Shao Y
    Int Immunopharmacol; 2023 Jun; 119():110285. PubMed ID: 37188605
    [No Abstract]   [Full Text] [Related]  

  • 33. Corrigendum to "Pathogenesis of Concanavalin A induced autoimmune hepatitis in mice" [Int. Immunopharmacol. 102 (2022) 108411].
    Hao J; Sun W; Xu H
    Int Immunopharmacol; 2022 Mar; 104():108550. PubMed ID: 35067473
    [No Abstract]   [Full Text] [Related]  

  • 34. Corrigendum to "IDO1: An important immunotherapy target in cancer treatment" [Int. Immunopharmacol. 47 (2017) 70-77].
    Li F; Zhang R; Li S; Liu J
    Int Immunopharmacol; 2017 Aug; 49():231. PubMed ID: 28457914
    [No Abstract]   [Full Text] [Related]  

  • 35. Corrigendum to "Icariin targets Nrf2 signaling to inhibit microglia-mediated neuroinflammation" [Int. Immunopharmacol. 73 (2019) 304-311].
    Zheng Y; Zhu G; He J; Wang G; Li D; Zhang F
    Int Immunopharmacol; 2020 Nov; 88():107004. PubMed ID: 32950402
    [No Abstract]   [Full Text] [Related]  

  • 36. Corrigendum to "Effect of chlorogenic acid on mast cell-dependent anaphylactic reaction" [Int. Immunopharmacol. 10 (2010) 1135-1141].
    Qin HD; Shi YQ; Liu ZH; Li ZG; Wang HS; Wang H; Liu ZP
    Int Immunopharmacol; 2019 Nov; 76():105863. PubMed ID: 31473097
    [No Abstract]   [Full Text] [Related]  

  • 37. Corrigendum to "Immune-enhancing effects of polysaccharides extracted from Lilium lancifolium Thunb" [Int. Immunopharmacol. 52 (2017) 119-126].
    Pan G; Xie Z; Huang S; Tai Y; Cai Q; Jiang W; Sun J; Yuan Y
    Int Immunopharmacol; 2018 May; 58():186. PubMed ID: 29599101
    [No Abstract]   [Full Text] [Related]  

  • 38. Corrigendum to "Circulating midkine in children with Henoch-Schönlein purpura: Clinical implications" [Int. Immunopharmacol. (2016) 246-250].
    Su Z; Lv X; Liu Y; Zhang J; Guan J; Gai Z
    Int Immunopharmacol; 2016 Dec; 41():145. PubMed ID: 27612398
    [No Abstract]   [Full Text] [Related]  

  • 39. Corrigendum to "A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors" [Int. Immunopharmacol. 108 (2022) 108775].
    Morimoto K; Yamada T; Morimoto Y; Ishikawa T; Asai J; Fujihara A; Arai A; Katoh N; Ukimura O; Hirano S; Itoh Y; Takayama K
    Int Immunopharmacol; 2022 Nov; 112():109232. PubMed ID: 36096994
    [No Abstract]   [Full Text] [Related]  

  • 40. Corrigendum to "Thalidomide ameliorate graft chronic rejection in an allogenic kidney transplant model" [Int. Immunopharmacol. 71 (2019) 32-39].
    Zhang Y; Yang Y; Li X; Chen D; Tang G; Men T
    Int Immunopharmacol; 2022 Jun; 107():108584. PubMed ID: 35484056
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.